“For the first time, the FDA openly acknowledged that they are rejecting some SEND datasets because the quality isn’t good enough. No ambiguity. Just a clear statement that quality matters, and that poor SEND has...
BOSTON, USA – 21 April 2026: d-wise (an Instem company), a leader in statistical computing infrastructure and clinical trial transparency, today announced the appointment of Christine Oliver as its President. Christine brings over two decades...
Instem, a leading provider of SaaS solutions for preclinical R&D, today announced the appointment of Szczepan Baran, VMD, MS, as Chief Scientific Officer. In the role, Szczepan will lead scientific and AI strategy across in...
Quality System ManagementRegulatory SubmissionSEND